SEC Form 4 · accession 0001209191-18-008224
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 6:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2018 | M | 3,594 | $109.14 | A | 56,118 | D | |
| Common StockF2,F3 | Feb 5, 2018 | S | 494 | $158.32 | D | 55,624 | D | |
| Common StockF3,F4 | Feb 5, 2018 | S | 700 | $159.62 | D | 54,924 | D | |
| Common StockF3,F5 | Feb 5, 2018 | S | 500 | $160.50 | D | 54,424 | D | |
| Common StockF3,F6 | Feb 5, 2018 | S | 500 | $161.51 | D | 53,924 | D | |
| Common StockF1,F7 | Feb 5, 2018 | S | 400 | $162.94 | D | 53,524 | D | |
| Common StockF1,F8 | Feb 5, 2018 | S | 900 | $164.12 | D | 52,624 | D | |
| Common Stock | Feb 5, 2018 | S | 100 | $164.71 | D | 52,524 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $109.14 | Feb 5, 2018 | M | 3,594 | D | — | Feb 2, 2025 | Common Stock | 3,594 | 14,375 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $158.32 (range $158.01 to $158.82).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $159.62 (range $159.18 to $160.06).
- F5Open market sales reported on this line occurred at a weighted average price of $160.50 (range $160.20 to $160.86).
- F6Open market sales reported on this line occurred at a weighted average price of $161.51 (range $161.32 to $161.85).
- F7Open market sales reported on this line occurred at a weighted average price of $162.94 (range $162.52 to $163.40).
- F8Open market sales reported on this line occurred at a weighted average price of $164.12 (range $163.65 to $164.53).
- F9The option vests in 16 quarterly installments from 2/3/2015.